Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 3:11:191.
doi: 10.3389/fphar.2020.00191. eCollection 2020.

Interactions Among Non-Coding RNAs in Diabetic Nephropathy

Affiliations
Review

Interactions Among Non-Coding RNAs in Diabetic Nephropathy

Tamil Selvi Loganathan et al. Front Pharmacol. .

Abstract

Diabetic Nephropathy (DN) is the most common cause of End-stage renal disease (ESRD). Although various treatments and diagnosis applications are available, DN remains a clinical and economic burden. Recent findings showed that noncoding RNAs (ncRNAs) play an important role in DN progression, potentially can be used as biomarkers and therapeutic targets. NcRNAs refers to the RNA species that do not encode for any protein, and the most known ncRNAs are the microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs). Dysregulation of these ncRNAs was reported before in DN patients and animal models of DN. Importantly, there are some interactions between these ncRNAs to regulate the crucial steps in DN progression. Here, we aimed to discuss the reported ncRNAs in DN and their interactions with critical genes in DN progression. Elucidating these ncRNAs regulatory network will allow for a better understanding of the molecular mechanisms in DN and how they can act as new biomarkers for DN and also as the potential targets for treatment.

Keywords: biomarkers; circRNA; diabetic nephropathy; kidney disease; lncRNA; miRNA.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic diagram showing the roles of noncoding RNAs in contributing to diabetic nephropathy. ECM, extracellular matrix; ER, Endoplasmic reticulum; black arrow, positive regulation; red arrow, negative regulation.

References

    1. Abu N., Jamal R. (2016). Circular RNAs as promising biomarkers: a mini-review. Front. Physiol. 7, 355. 10.3389/fphys.2016.00355 - DOI - PMC - PubMed
    1. Adams B. D., Parsons C., Walker L., Zhang W. C., Slack F. J. (2017). Targeting noncoding RNAs in disease. J. Clin. Invest. 127 (3), 761–771. 10.1172/JCI84424 - DOI - PMC - PubMed
    1. Ahmad N., Jamal R., Shah S. A., Abdul Gafor A. H., Murad N. A. A. (2019). Renin–angiotensin–aldosterone system gene polymorphisms and type 2 diabetic nephropathy in asian populations: an updated meta-analysis. Curr. Diabetes Rev. 15 (4), 263–276. 10.2174/1573399814666180709100411 - DOI - PubMed
    1. Alvarez M. L., DiStefano J. K. (2011). functional characterization of the plasmacytoma variant translocation 1 gene (PVT1) in diabetic nephropathy. PloS One 6 (4), e18671. 10.1371/journal.pone.0018671 - DOI - PMC - PubMed
    1. Alvarez M. L., DiStefano J. K. (2013). The role of non-coding RNAs in diabetic nephropathy: potential applications as biomarkers for disease development and progression. Diabetes Res. Clin. Pract. 99, 1–11. 10.1016/J.DIABRES.2012.10.010 - DOI - PubMed

LinkOut - more resources